Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-15
2005-02-15
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S416000
Reexamination Certificate
active
06855829
ABSTRACT:
Compounds which function as modulators, particularly, openers, of human KCNQ potassium channel proteins or polypeptides, particularly, central nervous system (CNS)-located KCNQ potassium channels, and heteromultimers thereof, and their use in the treatment of migraine are provided by the present invention. One novel type of potassium channel polypeptide openers provided by the present invention is the fluorooxindole compounds, described for the first time as therapeutics for the treatment of migraine by preventing the asynchronous firing of neurons. Other KCNQ potassium channel opener compounds that are also useful in the treatments of the invention include 2,4-disubstituted pyrimidine-5-carboxamide derivatives. One or more of the compounds according to the present invention may be utilized alone, in combination, or in conjunction with other treatment modalities for reducing, ameliorating and/or alleviating migraine or diseases similar to, or mechanistically related to, migraine, e.g., cluster headache.
REFERENCES:
patent: 5565483 (1996-10-01), Hewawasam et al.
patent: 5602169 (1997-02-01), Hewawasam et al.
patent: 5869509 (1999-02-01), Romine et al.
patent: 6034113 (2000-03-01), Hewawasam et al.
patent: 6117900 (2000-09-01), Rundfeldt et al.
patent: 6469042 (2002-10-01), Hewawasam et al.
patent: 20030181507 (2003-09-01), Jensen et al.
patent: WO9729748 (1997-08-01), None
patent: WO9907832 (1999-02-01), None
patent: WO0110380 (2001-02-01), None
patent: WO0110381 (2001-02-01), None
patent: WO0200217 (2002-01-01), None
patent: WO0230868 (2002-04-01), None
patent: WO02066426 (2002-08-01), None
No Author, Trilateral Project B3b Theme: Comparative study on “reach-through claims” [online]. San Francisco, California, Nov. 5-9, 2001, [retrieved on Jun. 26, 2003]. Ret'd Internet <http://www.uspto.gov/web/tws/B3b_reachthrough.pdf>.*
C. Biervert et al, “A Potassium Channel Mutation in Neonatal Human Epilepsy”,Science, 279:403-406 (1998).
D. D. Celentano et al., “Medication Use and Disability Among Migraineurs: A National Probability Sample Survey”,Headache, 32:223-228 (1992).
C. Charlier et al., “A pore mutation in novel KQT-like potassium channel gene in an idiopathic epilepsy family”,Nature Genetics, 18:53-55 (1998).
J. Edmeads et al., “Impact of Migraine and Tension-Type Headache on Life-Style, Consulting Behaviour, and Medication Use: A Canadian Population Survey”,Can. J. Neurol. Sci.20:131-137 (1993).
R. B. Lipton et al., “Undiagnosed Migraine Headaches, A Comparison of Sympton-Based and Reported Physician Diagnosis”,Arch Intern Med., 152:1273-1278 (1992).
R. B. Lipton and W. F. Stewart, “Migraine in the United States: A review of epidemiology and health care use”,Neurology, 43(suppl3):S6-S10 (1993).
R. B. Lipton and W. F. Stewart, “Medical Consultation for Migraine”,Neurology[abstract], 44(suppl2):199 (1994).
B. K. Rasmussen et al., “Impact of headache on sickness absence and utilization of medical services: a Danish population study”,J Epidemiol Community Health, 46:443-446 (1992).
B.K. Rasmussen and N. Breslau, “Migraine: Epidemiology”,The Headaches, Eds. Olesen, Tfelt-Hansen, Welch, New York, NY: Raven Press; Chptr. 22:169-173 (1993).
N. A. Singh et al., “A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns”,Nature Genetics, 18:25-29 (1998).
W. F. Stewart et al., “Prevalence of Migraine Headache in the United States, Relation ot Age, Income, Race, and Other Sociodemographic Factors”,JAMA, 267:64-69 (1992).
W.F. Stewart et al., “Migraine heterogeneity, Disability, pain intensity, and attack frequency and duration”,Neurology, 44(suppl 4):S24-S39 (1994).
H.-S. Wang et al., “KCNQ2 and KCNQ3 Potassium Channel Subunits: Modular Correlates of the M-Channel”,Science, 282, pp. 1890-1893 (1998).
Dworetzky Steven I.
Gribkoff Valentin K.
Hewawasam Piyasena
Kinney Gene G.
Algieri Aldo A.
Bristol--Myers Squibb Company
Lamerdin John A.
McKenzie Thomas C.
LandOfFree
3-fluoro-2-oxindole modulators of KCNQ potassium channels... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-fluoro-2-oxindole modulators of KCNQ potassium channels..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-fluoro-2-oxindole modulators of KCNQ potassium channels... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461876